

7. Literaturverzeichnis

1. Bertelmann E, Kojetinsky C, *Posterior capsule opacification and anterior capsule opacification*. Curr Opin Ophthalmol, 2001. **12**(1): p. 35-40.
2. Tetz M R, Nimsger C, *Posterior capsule opacification. Part 2: Clinical findings*. J Cataract Refract Surg, 1999. **25**(12): p. 1662-74.
3. Pandey S K, Apple D J, Werner L, et al., *Posterior capsule opacification: a review of the aetiopathogenesis, experimental and clinical studies and factors for prevention*. Indian J Ophthalmol, 2004. **52**(2): p. 99-112.
4. Keech R V, Tongue A C, Scott W E, *Complications after surgery for congenital and infantile cataracts*. Am J Ophthalmol, 1989. **108**(2): p. 136-41.
5. *Duane's Ophthalmology*. CD-ROM ed, ed. W. Tasman, Jaeger, E. A. 2001, Philadelphia: Lippincott Williams & Wilkins.
6. Grehn F, *Augenheilkunde*. 28 ed. 2003, Berlin, Heidelberg, New York: Springer-Verlag.
7. Migliori M E, Beckman H, Channell M M, *Intraocular pressure changes after neodymium-YAG laser capsulotomy in eyes pretreated with timolol*. Arch Ophthalmol, 1987. **105**(4): p. 473-5.
8. Fourman S, Apisson J, *Late-onset elevation in intraocular pressure after neodymium-YAG laser posterior capsulotomy*. Arch Ophthalmol, 1991. **109**(4): p. 511-3.
9. Ficker L A, Vickers S, Capon M R, et al., *Retinal detachment following Nd:YAG posterior capsulotomy*. Eye, 1987. **1** (Pt 1): p. 86-9.
10. Rickman-Barger L, Florine C W, Larson R S, et al., *Retinal detachment after neodymium:YAG laser posterior capsulotomy*. Am J Ophthalmol, 1989. **107**(5): p. 531-6.
11. Behrendt S, Giess L, Duncker G, *Incidence of retinal detachment after treatment with the Nd:YAG laser*. Fortschr Ophthalmol, 1991. **88**(6): p. 809-11.
12. Liesenhoff O, Kampik A, *Risk of retinal detachment in pseudophakia and axial myopia*. Ophthalmologe, 1994. **91**(6): p. 807-10.

13. Tielsch J M, Legro M W, Cassard S D, et al., *Risk factors for retinal detachment after cataract surgery. A population-based case-control study.* Ophthalmology, 1996. **103**(10): p. 1537-45.
14. Auffarth G U, Nimsgern C, Tetz M R, et al., *Analysis of energy levels for Nd:YAG laser capsulotomy in secondary cataract.* Ophthalmologe, 2000. **97**(1): p. 1-4.
15. Ruetsch Y A, Boni T, Borgeat A, *From cocaine to ropivacaine: the history of local anesthetic drugs.* Curr Top Med Chem, 2001. **1**(3): p. 175-82.
16. Mielke J, Schlote T, *Subconjunctival anaesthesia using cocaine or mepivacaine for cyclocryotherapy in advanced glaucoma.* Klin Monatsbl Augenheilkd, 2004. **221**(1): p. 24-8.
17. AstraZeneca, *Xylonest®/- Adrenalin Fachinformation des Arzneimittel-Kompendium der Schweiz®.* 2007, Documed AG: Basel.
18. Ramsay R C, Knobloch W H, *Ocular perforation following retrobulbar anesthesia for retinal detachment surgery.* Am J Ophthalmol, 1978. **86**(1): p. 61-4.
19. Kimble J A, Morris R E, Witherspoon C D, et al., *Globe perforation from peribulbar injection.* Arch Ophthalmol, 1987. **105**(6): p. 749.
20. Modarres M, Parvaresh M M, Hashemi M, et al., *Inadvertent globe perforation during retrobulbar injection in high myopes.* Int Ophthalmol, 1997. **21**(4): p. 179-85.
21. Vohra S B, Good P A, *Altered globe dimensions of axial myopia as risk factors for penetrating ocular injury during peribulbar anaesthesia.* Br J Anaesth, 2000. **85**(2): p. 242-5.
22. Auffarth G U, Rabsilber T M, Reuland A J, *New methods for the prevention of posterior capsule opacification.* Ophthalmologe, 2005. **102**(6): p. 579-86.
23. Rabsilber T M, Auffarth G U, *Pharmacological means to prevent secondary cataract.* Klin Monatsbl Augenheilkd, 2006. **223**(7): p. 559-67.
24. Apple D J, Solomon K D, Tetz M R, et al., *Posterior capsule opacification.* Surv Ophthalmol, 1992. **37**(2): p. 73-116.
25. Hollick E J, Spalton D J, Ursell P G, et al., *Lens epithelial cell regression on the posterior capsule with different intraocular lens materials.* Br J Ophthalmol, 1998. **82**(10): p. 1182-8.
26. Apple D J, *Influence of intraocular lens material and design on postoperative intracapsular cellular reactivity.* Trans Am Ophthalmol Soc, 2000. **98**: p. 257-83.

27. Liekfeld A, Pahms N, Torun N, et al., *Evaluation of a human capsular bag model for secondary cataract determination after intraocular lens implantation*. Graefes Arch Clin Exp Ophthalmol, 2005. **243**(1): p. 43-8.
28. Latz C, Migonney V, Pavon-Djavid G, et al., *Inhibition of lens epithelial cell proliferation by substituted PMMA intraocular lenses*. Graefes Arch Clin Exp Ophthalmol, 2000. **238**(8): p. 696-700.
29. Nishi O, Nishi K, Sakanishi K, *Inhibition of migrating lens epithelial cells at the capsular bend created by the rectangular optic edge of a posterior chamber intraocular lens*. Ophthalmic Surg Lasers, 1998. **29**(7): p. 587-94.
30. Tassignon M J, Gobin L, Leysen I, et al., *Secondary cataract: a problem resolved*. Bull Mem Acad R Med Belg, 2006. **161**(7-9): p. 469-78; discussion 478.
31. Pleyer U, Yang J, Knapp S, et al., *Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty*. Graefes Arch Clin Exp Ophthalmol, 2005. **243**(5): p. 450-5.
32. Rieck P W, Kriegsch J, Jaeckel C, et al., *Effect of suramin on proliferation and migration of lens epithelial cells in vitro*. Ophthalmologe, 2004. **101**(1): p. 73-9.
33. Inan U U, Bozkurt E, Ozturk F, et al., *Effect of diclofenac on prevention of posterior capsule opacification in human eyes*. Can J Ophthalmol, 2006. **41**(5): p. 624-9.
34. Inan U U, Ozturk F, Kaynak S, et al., *Prevention of posterior capsule opacification by retinoic acid and mitomycin*. Graefes Arch Clin Exp Ophthalmol, 2001. **239**(9): p. 693-7.
35. Pierschbacher M D, Ruoslahti E, *Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule*. Nature, 1984. **309**(5963): p. 30-3.
36. Kojetinsky C, Baatz H, Pleyer U, et al., *In vitro bovine and human lens epithelial cell culture studies on inhibition of posterior capsule opacification using a cyclic RGD peptide*. Ophthalmologe, 2001. **98**(8): p. 731-5.
37. Inan U U, Ozturk F, Kaynak S, et al., *Prevention of posterior capsule opacification by intraoperative single-dose pharmacologic agents*. J Cataract Refract Surg, 2001. **27**(7): p. 1079-87.
38. Faschinger C, Mossbock G, *Myopia and glaucoma*. Wien Med Wochenschr, 2007. **157**(7-8): p. 173-7.

39. Mitchell P, Hourihan F, Sandbach J, et al., *The relationship between glaucoma and myopia: the Blue Mountains Eye Study*. Ophthalmology, 1999. **106**(10): p. 2010-5.
40. Leske M C, Connell A M, Wu S Y, et al., *Risk factors for open-angle glaucoma. The Barbados Eye Study*. Arch Ophthalmol, 1995. **113**(7): p. 918-24.
41. O'Donoghue E P, *A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group*. Br J Ophthalmol, 2000. **84**(6): p. 579-82.
42. Orzalesi N, Rossetti L, Invernizzi T, et al., *Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension*. Invest Ophthalmol Vis Sci, 2000. **41**(9): p. 2566-73.
43. Thieme H, *Drug therapy in the treatment of glaucoma*. Klin Monatsbl Augenheilkd, 2006. **223**(9): p. R73-8; quiz R79-80.
44. Smith W L, *Prostanoid biosynthesis and mechanisms of action*. Am J Physiol, 1992. **263**(2 Pt 2): p. F181-91.
45. Milvae R A, *Inter-relationships between endothelin and prostaglandin F2alpha in corpus luteum function*. Rev Reprod, 2000. **5**(1): p. 1-5.
46. Löffler G, Petrides P E, *Biochemie und Pathobiochemie*. 6 ed. 1998, Berlin, Heidelberg, New York: Springer-Verlag.
47. Rieck P, Edelmann B, Schmidt S, et al., *Effect of prostaglandin F2 alpha on proliferation of corneal endothelial cells in vitro*. Ophthalmologe, 2001. **98**(12): p. 1157-61.
48. Sakurai M, Higashide T, Takahashi M, et al., *Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost*. Ophthalmology, 2007. **114**(6): p. 1039-45.
49. Crowston J G, Aihara M, Lindsey J D, et al., *Effect of latanoprost on outflow facility in the mouse*. Invest Ophthalmol Vis Sci, 2004. **45**(7): p. 2240-5.
50. Crowston J G, Lindsey J D, Aihara M, et al., *Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor*. Invest Ophthalmol Vis Sci, 2004. **45**(10): p. 3555-9.
51. Crowston J G, Lindsey J D, Morris C A, et al., *Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice*. Invest Ophthalmol Vis Sci, 2005. **46**(12): p. 4571-7.

52. Thieme H, Schimmat C, Munzer G, et al., *Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility*. Invest Ophthalmol Vis Sci, 2006. **47**(3): p. 938-45.
53. Supuran C T, Scozzafava A, Casini A, *Carbonic anhydrase inhibitors*. Med Res Rev, 2003. **23**(2): p. 146-89.
54. Pastorekova S, Parkkila S, Pastorek J, et al., *Carbonic anhydrases: current state of the art, therapeutic applications and future prospects*. J Enzyme Inhib Med Chem, 2004. **19**(3): p. 199-229.
55. Supuran C T, Scozzafava A, *Carbonic anhydrases as targets for medicinal chemistry*. Bioorg Med Chem, 2007. **15**(13): p. 4336-50.
56. Mincione F, Scozzafava A, Supuran C T, *The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents*. Curr Top Med Chem, 2007. **7**(9): p. 849-54.
57. Thieme H, Nass J U, Nuskovski M, et al., *The effects of the carbonic anhydrase inhibitors methazolamide, diclofenamide and dorzolamide on trabecular meshwork and ciliary muscle contractility*. Exp Eye Res, 1999. **69**(4): p. 455-8.
58. Aoyama Y, Motoki M, Hashimoto M, *Effect of various anti-glaucoma eyedrops on human corneal epithelial cells*. Nippon Ganka Gakkai Zasshi, 2004. **108**(2): p. 75-83.
59. Lindl T, *Zell- und Gewebekultur*. 5 ed. 2002, Heidelberg, Berlin: Spektrum Akademischer Verlag GmbH.
60. Griffiths J P, Pirt S J, *The uptake of amino acids by mouse cells (strain LS) during growth in batch culture and chemostat culture: the influence of cell growth rate*. Proc R Soc Lond B Biol Sci, 1967. **168**(13): p. 421-38.
61. Loftsson T, Jarvinen T, *Cyclodextrins in ophthalmic drug delivery*. Adv Drug Deliv Rev, 1999. **36**(1): p. 59-79.
62. Sjoquist B, Stjernschantz J, *Ocular and systemic pharmacokinetics of latanoprost in humans*. Surv Ophthalmol, 2002. **47 Suppl 1**: p. S6-12.
63. Hakeda Y, Hotta T, Kurihara N, et al., *Prostaglandin E1 and F2 alpha stimulate differentiation and proliferation, respectively, of clonal osteoblastic MC3T3-E1 cells by different second messengers in vitro*. Endocrinology, 1987. **121**(6): p. 1966-74.
64. Yang T J, Dale J B, Machanoff R, *Effects of prostaglandins E1, E2, and F2alpha on the growth of leukaemia cells in culture*. J Cell Sci, 1976. **20**(1): p. 199-206.

65. Nakamura A, Chiba T, Yamatani T, et al., *Prostaglandin E2 and F2 alpha inhibit growth of human gastric carcinoma cell line KATO III with simultaneous stimulation of cyclic AMP production*. Life Sci, 1989. **44**(1): p. 75-80.
66. Phipps R P, Lee D, Schad V, et al., *E-series prostaglandins are potent growth inhibitors for some B lymphomas*. Eur J Immunol, 1989. **19**(6): p. 995-1001.
67. Kawamura M, Koshihara Y, *Prostaglandin D2 strongly inhibits growth of murine mastocytoma cells*. Prostaglandins Leukot Med, 1983. **12**(1): p. 85-93.
68. Sakai T, Yamaguchi N, Kawai K, et al., *Prostaglandin D2 inhibits the proliferation of human neuroblastoma cells*. Cancer Lett, 1983. **17**(3): p. 289-94.
69. Ikai K, Ujihara M, Kashihara M, et al., *Inhibition of the proliferation of transformed epidermal cells in culture by various prostaglandins*. J Invest Dermatol, 1987. **89**(1): p. 69-72.
70. Simkin N J, Jelinek D F, Lipsky P E, *Inhibition of human B cell responsiveness by prostaglandin E2*. J Immunol, 1987. **138**(4): p. 1074-81.
71. Nakahama K, Morita I, Murota S, *Effects of endogenously produced arachidonic acid metabolites on rat mesangial cell proliferation*. Prostaglandins Leukot Essent Fatty Acids, 1994. **51**(3): p. 177-82.
72. Conconi M T, Spinazzi R, Tommasini M, et al., *Prostaglandin F2 alpha can modulate the growth and the differentiation of bovine corneal epithelial cells cultured in vitro*. Ann Anat, 2001. **183**(6): p. 567-73.